
SI-BONE Inc (SIBN) Stock Forecast & Price Target
SI-BONE Inc (SIBN) Analyst Ratings
Bulls say
SI-BONE Inc. has demonstrated a substantial financial performance in the second quarter of 2025, with revenue increasing approximately 23% year-over-year to $46.4 million, reflecting strong demand for its medical device products. The company's gross margin also showed improvement, rising around 80 basis points year-over-year to 79.8%, indicating enhanced efficiency in its operations. Additionally, an increase of approximately 25% in the number of surgeons utilizing SI-BONE's products further underscores the company's growing market penetration and potential for sustained revenue growth.
Bears say
The financial outlook for SI-BONE Inc is hindered by a stagnating global spine market, which has encountered pricing pressures and procedural challenges that have resulted in growth rates limited to the low single digits. Moreover, the potential shift in reimbursement practices by payors toward competitive products poses a significant risk to SI-BONE's market share in sacroiliac joint fusion procedures, further jeopardizing its top-line revenue. Continued expectations of prevailing market headwinds could exacerbate these issues, leading to ongoing constraints on the company's financial performance.
This aggregate rating is based on analysts' research of SI-BONE Inc and is not a guaranteed prediction by Public.com or investment advice.
SI-BONE Inc (SIBN) Analyst Forecast & Price Prediction
Start investing in SI-BONE Inc (SIBN)
Order type
Buy in
Order amount
Est. shares
0 shares